Go to
JCI Insight
Citations to this article
Peter Dietrich, … , Anja K. Bosserhoff, Claus Hellerbrand
Published January 30, 2020
Citation Information: J Clin Invest. 2020;130(5):2509-2526. https://doi.org/10.1172/JCI131919.
Citation Information: J Clin Invest. 2020;130(5):2509-2526. https://doi.org/10.1172/JCI131919.
Abstract
Hepatocellular carcinoma (HCC) is clearly age-related and represents one of the deadliest cancer types worldwide. As a result of globally increasing risk factors including metabolic disorders, the incidence rates of HCC are still rising. However, the molecular hallmarks of HCC remain poorly understood. Neuropeptide Y (NPY) and NPY receptors represent a highly conserved, stress-activated system involved in diverse cancer-related hallmarks including aging and metabolic alterations, but its impact on liver cancer had been unclear. Here, we observed increased expression of NPY5 receptor (Y5R) in HCC, which correlated with tumor growth and survival. Furthermore, we found that its ligand NPY was secreted by peritumorous hepatocytes. Hepatocyte-derived NPY promoted HCC progression by Y5R activation. TGF-β1 was identified as a regulator of NPY in hepatocytes and induced Y5R in invasive cancer cells. Moreover, NPY conversion by dipeptidylpeptidase 4 (DPP4) augmented Y5R activation and function in liver cancer. The TGF-β/NPY/Y5R axis and DPP4 represent attractive therapeutic targets for controlling liver cancer progression.
Authors
Peter Dietrich, Laura Wormser, Valerie Fritz, Tatjana Seitz, Monica De Maria, Alexandra Schambony, Andreas E. Kremer, Claudia Günther, Timo Itzel, Wolfgang E. Thasler, Andreas Teufel, Jonel Trebicka, Arndt Hartmann, Markus F. Neurath, Stephan von Hörsten, Anja K. Bosserhoff, Claus Hellerbrand
Citation information
Citations to this article (19)
| Title and authors | Publication | Year |
|---|---|---|
|
Neuropeptide Y in cancer—biological functions and potential clinical implications
Sigorski D, Sejda A, Abualsaud N, Krawczyk E, Izycka-Swieszewska E, Kitlinska J |
Cancer Metastasis Reviews | 2025 |
|
Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis
Chambers CR, Watakul S, Schofield P, Howell AE, Zhu J, Tran AM, Kuepper N, Reed DA, Murphy KJ, Channon LM, Pereira BA, Tyma VM, Lee V, Trpceski M, Henry J, Melenec P, Abdulkhalek L, Nobis M, Metcalf XL, Ritchie S, Cadell A, Stoehr J, Magenau A, Chacon-Fajardo D, Chitty JL, O\u2019Connell S, Zaratzian A, Tayao M, Da Silva A, Lyons RJ, Goldstein LD, Dale A, Rookyard A, Connolly A, Crossett B, Tran YT, Kaltzis P, Vennin C, Dinevska M, Croucher DR, Samra J, Mittal A, Weatheritt RJ, Philp A, Del Monte-Nieto G, Zhang L, Enriquez RF, Cox TR, Shi YC, Pinese M, Waddell N, Sim HW, Chtanova T, Wang Y, Joshua AM, Chantrill L, Evans TR, Gill AJ, Morton JP, Pajic M, Christ D, Herzog H, Timpson P, Herrmann D |
Science Advances | 2025 |
|
ASS1 is a hub gene and possible therapeutic target for regulating metabolic dysfunction-associated steatotic liver disease modulated by a carbohydrate-restricted diet.
Chen S, Bi Y, Zhang L |
Molecular diversity | 2025 |
|
"Neprilysin-dependent neuropeptide y cleavage in the liver promotes fibrosis by blocking npy-receptor 1"
Cristina Ortiz, Sabine Klein, Winfried Reul, Fernando Magdaleno, Stefanie Gröschl, Peter Dietrich, Robert Schierwagen, Frank Uschner, Sandra Torres, Olaf Tyc, Maximilian Brol, Stefan Zeuzem, Christoph Welsch, Marko Poglitsch, Claus Hellerbrand, Mercedes Alfonso-Prieto, Fabio Mira, Ulrich Keller, Anja Tetzner, Andrew Moore, Thomas Walther, Jonel Trebicka |
Cell Reports | 2023 |
|
Neuropeptide Y Peptide Family and Cancer: Antitumor Therapeutic Strategies
Sánchez ML, Rodríguez FD, Coveñas R |
International journal of molecular sciences | 2023 |
|
Hypoxia-activated neuropeptide Y/Y5 receptor/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma
C Lu, A Mahajan, S Hong, S Galli, S Zhu, J Tilan, N Abualsaud, M Adnani, S Chung, N Elmansy, J Rodgers, O Rodriguez, C Albanese, H Wang, M Regan, V Zgonc, J Blancato, E Krawczyk, G Gallicano, M Girgis, A Cheema, E Iżycka-Świeszewska, L Cavalli, S Pack, J Kitlinska |
Nature Communications | 2022 |
|
Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
P Busek, J Duke-Cohan, A Sedo |
Cancers | 2022 |
|
Curcumin and berberine co-loaded liposomes for anti-hepatocellular carcinoma therapy by blocking the cross-talk between hepatic stellate cells and tumor cells
Wu J, Qi C, Wang H, Wang Q, Sun J, Dong J, Yu G, Gao Z, Zhang B, Tian G |
Frontiers in pharmacology | 2022 |
|
Role of Fibroblast Growth Factors in the Crosstalk of Hepatic Stellate Cells and Uveal Melanoma Cells in the Liver Metastatic Niche
Seitz T, John N, Sommer J, Dietrich P, Thasler WE, Hartmann A, Evert K, Lang SA, Bosserhoff A, Hellerbrand C |
International journal of molecular sciences | 2022 |
|
Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma
Prexler C, Knape MS, Erlewein-Schweizer J, Roll W, Specht K, Woertler K, Weichert W, von Luettichau I, Rossig C, Hauer J, Richter GH, Weber W, Burdach S |
Cancers | 2022 |
|
Cellular Senescence in Hepatocellular Carcinoma: The Passenger or the Driver?
Cai X, Guillot A, Liu H |
Cells | 2022 |
|
Neuropeptide Y and its receptors in prostate cancer: associations with cancer invasiveness and perineural spread.
Sigorski D, Wesołowski W, Gruszecka A, Gulczyński J, Zieliński P, Misiukiewicz S, Kitlińska J, Iżycka-Świeszewska E |
Journal of Cancer Research and Clinical Oncology | 2022 |
|
Overexpression of Taspase 1 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma
J Jiang, B Liu, R Liu, W Yang |
Cancer management and research | 2021 |
|
Xanthohumol, a Prenylated Chalcone Derived from Hops, Inhibits Growth and Metastasis of Melanoma Cells
T Seitz, C Hackl, K Freese, P Dietrich, A Mahli, RM Thasler, WE Thasler, SA Lang, AK Bosserhoff, C Hellerbrand |
Cancers | 2021 |
|
Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11
A Gaza, V Fritz, L Malek, L Wormser, N Treiber, J Danner, AE Kremer, WE Thasler, J Siebler, G Meister, MF Neurath, C Hellerbrand, AK Bosserhoff, P Dietrich |
Neoplasia (New York, N.Y.) | 2021 |
|
Neuropeptide Y/Y5 Receptor Pathway Stimulates Neuroblastoma Cell Motility Through RhoA Activation
N Abualsaud, L Caprio, S Galli, E Krawczyk, L Alamri, S Zhu, GI Gallicano, J Kitlinska |
Frontiers in Cell and Developmental Biology | 2021 |
|
Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma
V Fritz, L Malek, A Gaza, L Wormser, M Appel, AE Kremer, WE Thasler, J Siebler, MF Neurath, C Hellerbrand, AK Bosserhoff, P Dietrich |
Cancers | 2021 |
|
Binding of Natural Peptide Ligands to the Neuropeptide Y 5 Receptor
S Rudolf, K Kaempf, O Vu, J Meiler, A BeckSickinger, I Coin |
Angewandte Chemie (International ed. in English) | 2021 |
|
High DPP4 expression predicts poor prognosis in patients with low-grade glioma
Y Han, Y Sun, Y Zhang, Q Xia |
Molecular Biology Reports | 2020 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)